Perampanel + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy
Conditions
Epilepsy
Trial Timeline
Sep 1, 2010 → Nov 1, 2014
NCT ID
NCT01161524About Perampanel + Placebo
Perampanel + Placebo is a phase 2 stage product being developed by Eisai for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT01161524. Target conditions include Epilepsy.
What happened to similar drugs?
20 of 20 similar drugs in Epilepsy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02220972 | Approved | Withdrawn |
| NCT01618695 | Phase 3 | Completed |
| NCT01161524 | Phase 2 | Completed |
| NCT00566462 | Phase 2 | Terminated |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 35 |
| Lacosamide | UCB | Phase 3 | 40 |
| Zonisamide + Placebo | Eisai | Phase 3 | 32 |
| Zonegran | Eisai | Approved | 35 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| perampanel | Eisai | Approved | 35 |
| E2007 + Placebo | Eisai | Phase 2 | 35 |
| Placebo + Rufinamide | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| Perampanel Oral Tablet | Eisai | Approved | 43 |
| perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Approved | 43 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| Perampanel | Eisai | Phase 2 | 35 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 43 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 35 |